17 - 20 Jun 2024 | Amsterdam

Inclusive clinical trials: Why we really shouldn't still be talking about this in 2024 (but have to!)

Speakers:

Adama Ibrahim
VP Digital Strategy & Change ManagementNovo Nordisk
James O'Shaughnessy
Senior PartnerNewmarket Strategy
Dina Gifkins
Senior Director, Oncology Therapeutic HeadJohnson & Johnson
Cristina Duran
PresidentEvinova
Michelle Longmire
Co-Founder & CEOMedable

About this Session:

In 2022, the US’s National Academy of Sciences, Engineering & Medicine (NASEM) released a damning report into underrepresentation in clinical trials. "While progress has been made with representation of white women in clinical trials and clinical research, there has been little progress in the last three decades to increase participation of racial and ethnic minority population groups." Whilst we celebrate diversity in Europe, from race to gender, sexuality to age, participants in clinical trials remain overwhelmingly white and male. However, until interest and investment to improve diversity and representativeness in trials comes to the forefront, the goals of diversification remain poorly articulated and understood. We all know how important diversity is, but how exactly can we make clinical trials attractive to all?

More Sessions

Yes it is: The future of health is female
18 Jun 2024
HLTH Europe 2024: Yes it is: The future of health is female
The Beat: Microsoft - When Systems Speak to each other - The CIO View on Interoperability
18 Jun 2024
HLTH Europe 2024: The Beat: Microsoft - When Systems Speak to each other - The CIO View on Interoperability

Next Events

ViVE 2025
ViVE 2025
HLTH Europe 2025
HLTH Europe 2025